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seroprevalence and serostability of 37 different HPV types over 4½ years in an Australian population-based
study. Sera and data were analyzed for 390 people who had never been diagnosed with SCC and had blood
collected in 1992, 1993 and 1996.
Eighty-six percent of participants were seropositive to at least one of the 37 HPV types at baseline. HPV-4
was the type with the highest seroprevalence (41%), followed by HPV-38 and HPV-8 (both 33%). Over 90% of
people retained their baseline serostatus during the 4½ year follow-up. Highest serostability was observed
for HPV-88 (99.7% stayed seropositive or seronegative), while HPV-65 was least stable with 17% altering
their serostatus during follow-up.
Seroprevalence to cutaneous HPV types are relatively stable over time, and a single measure can be used as a
reasonable marker of long-term antibody status.ical Research, 300 Herston Rd,
3502.
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Papillomaviruses are a diverse, epitheliotropic group of viruses
recognized as the causative agents of warts, cervical cancer and head
and neck cancers. Over 120 different human papillomavirus (HPV)
types have been fully characterized and they can be classiﬁed into
phylogenetic groups which largely parallel with their tissue tropism
(Bernard et al., 2010; de Villiers et al., 2004). The mucosal
papillomaviruses are found in the alpha genus, and papillomaviruses
infecting the skin are found in the beta, gamma, mu and nu genera
with a few skin HPV types in the alpha genus.
An etiological role of HPV in skin cancer has been postulated,
although not yet proven (2007; Bouvard et al., 2009). The association
was ﬁrst suggested on the basis of studies in patients who suffer from
a very rare inherited disorder, epidermodysplasia verruciformis (EV).
Patients with EV have mutations in 2 genes that render them
susceptible to HPV infection, leading to development of squamous
cell carcinomas (SCCs) at a young age (Ramoz et al., 2002). Evidence
that HPV may be associated with cutaneous SCC in people without EV
came ﬁrstly from studies of immunosuppressed organ transplant
recipients. These patients have a high prevalence of HPV infection and
up to 100-fold increased risk of SCC and a 10-fold increased risk ofbasal cell carcinoma (BCC) of the skin, resulting in a reversal of the SCC
to BCC ratio compared to the general population (Kiviat, 1999).
Clinical and histological features of lesions from transplant recipients
suggest that SCCs develop from the progression of viral warts through
dysplastic lesions to SCC (Barr et al., 1989). Beta HPV types have been
identiﬁed in up to 80% of SCCs, 90% of actinic keratoses and 60% of
BCCs (Berkhout et al., 2000; de Jong-Tieben et al., 2000; Harwood
et al., 2000). Studies in immunocompetent patients centered initially
on examination of skin lesions, ﬁnding that while the prevalence of
HPV DNA was lower than in transplant recipients, it was nevertheless
substantial, with up to 50% of SCCs in immunocompetent populations
showing evidence of HPV infection (Asgari et al., 2008; Forslund et al.,
2007).
Despite this suggestive evidence, no high-risk types have emerged
as being clearly associated with the development of skin cancer in
epidemiological studies. This may be partly because there is a paucity
of information about the appropriate marker of infection. Measure-
ments of HPV DNA in eyebrow hairs or skin swabs have been used
(Antonsson et al., 2000, 2003; Chen et al., 2008; de Koning et al.,
2007), but these samples may not be indicative of infection at the site
where the lesion arose. Furthermore, the very high prevalence of HPV
DNA in people without skin cancer may indicate that these samples
largely measure biologically irrelevant infection (Antonsson et al.,
2000, 2003; Chen et al., 2008; de Koning et al., 2007).
More recently HPV antibodies have been used as an indicator of
prior HPV infection in case-control and cohort studies (Casabonne
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et al., 2006; Michael et al., 2008; Waterboer et al., 2008, 2009).
Antibodies to the mucosal HPV types have been well studied and are
an indicator of past infection (Dillner, 1999). However, only 50% of
women infected with the mucosal high-risk type HPV-16 develop
antibodies to HPV-16, and this can take several months after the
infection is established. Once the HPV-16 antibodies are present, low
but stable titers are detectable over long periods of time (Dillner,
1999). In contrast, information about serostability over time to
cutaneous HPV infections is limited, limiting the interpretation of
epidemiological studies.
To add to the knowledge base about HPV antibodies, and thereby
facilitate their rational use in research, we aimed to determine the
prevalence, determinants and stability of antibody status to 37 HPV
types in a population-based longitudinal study of 390 people from
Queensland, Australia.
Results
Characteristics of the study population
The mean age at baseline of the 390 participants was 50 years (SD
13), and 219 (56%) were female. Distributions of other characteristics,
such as skin color, type of occupation and smoking are presented in
Table 1. Eleven (3%) of the 390 participants analyzed were diagnosed
at baseline with BCC and 39 (10%) were diagnosed with BCC during
the follow-up period (1992–1996). One-hundred-and-ﬁfty (38%)
people were diagnosed with actinic keratosis at baseline (Table 1).
HPV seroprevalence
Eighty-six percent (n=336) of participants were seropositive to
at least one of the 37 HPV types tested in 1992 and 1993, and 89%
(n=346) in 1996. Twenty-ﬁve (6.4%; 20 women and 5 men) of theTable 1
Characteristics of study population at base line.
Characteristic % (n)
n 390
Age (years), mean (SD) 50 (SD 13)
Age distribution Up to 40 24 (94)
41–50 30 (117)
51–60 22 (86)
61–70 16 (62)
71 and older 8 (31)
Eye color Blue/grey 42 (163)
Hazel/green 39 (152)
Light brown 7 (29)
Dark brown 12 (45)
Hair color Blonde/Light brown 49 (193)
Red 8 (31)
Dark brown/Black 43 (166)
Skin color Fair 52 (204)
Medium 38 (149)
Olive, brown or black 10 (37)
Skin response after exposure
to strong sun
Burn only 19 (75)
Burn, then tan 70 (274)
Tan only 11 (41)
Type of occupation Mainly outdoors 17 (66)
Outdoors and indoors 38 (147)
Mainly indoors 45 (177)
Smoking Never smoked 57 (218)
Current smoker 10 (39)
Ex-smoker 33 (128)
Basal cell carcinoma No 97 (379)
Yes 3 (11)
Actinic keratosis No 62 (240)
Yes 38 (150)
Numbers may not sum to total due to missing data.participants were seronegative to all HPV types in all three samples
during the 4½ year follow-up.
HPV-4 had the highest seroprevalence (41%), followed by HPV-38
(33%), HPV-8 (33%), HPV-65 (29%) and HPV-49 (26%). The lowest
seroprevalences were found for HPV-88 (0.5%), HPV-14 (1.3%) and
HPV-93 (3.6%; Fig. 1).
Phylogenetically, the overall prevalence was highest for the beta
HPV types (65%) and lowest for the two alpha skin HPV types (15%;
Table 2).
The MFI values at baseline are shown in Supplementary Table 1.
The seroprevalence was relatively insensitive to change in the MFI
value used as the cut-off to determine seropositivity (100MFI and 500
MFI instead of 200 MFI). Changing the cut-off value did not alter the
seroprevalence by more than 15% for any HPV type and in most cases
not more than 10%. The biggest changes in seroprevalence were seen
for HPV-65, (increased from 29% to 44% (100 MFI)) and for HPV-4
(decreased by 14% (500 MFI)). MFI distribution of four selected HPV
types are presented in Supplementary Fig. 1.
Characteristics and life-style factors associated with HPV seroprevalence
Men had higher overall seroprevalence thanwomen (19% and 14%,
respectively). Men also had higher seroprevalence than women for
most individual HPV types (Fig. 1). This difference was signiﬁcant
(pb0.05) for the beta types HPV-8, HPV-15, HPV-23, HPV-38, HPV-49
and HPV-76, the gamma types HPV-4 and HPV-95, and the mu
types HPV-1 and HPV-63. Seroprevalence was marginally and non-
signiﬁcantly higher in women than in men for the beta type HPV-93,
gamma types HPV-50 and HPV-88, and the alpha types HPV-11 and
HPV-16.
A signiﬁcantly higher proportion of men were beta HPV positive
(73%) compared with women (58%; p=0.008). Seropositivity to at
least one of the three HPV types from the mu and nu genera was also
more prevalent in men than in women (46% versus 28%, p=0.0001).
A higher proportion of men (66%) were also seropositive to at least
one HPV type from the gamma group compared to women (55%;
p=0.019). Beta HPV seroprevalence was found to signiﬁcantly
increase with age (p=0.022), while seroprevalence to at least one
of the HPV types of the mu/nu, and the skin and mucosal alpha HPV
groups were decreasing with age (p=0.018, 0.017 and 0.0002,
respectively). There was no association between age and seropreva-
lence for the gamma HPV group (Table 2).
People seropositive to the mucosal type HPV-11 were signiﬁcantly
younger than those who were seronegative (mean 44 vs. 51 years;
pb0.001) which was also the case for HPV-1 (mean age seropositive
47 years and seronegative 51 years; p=0.033). There were no
differences in prevalence according to age for any of the other HPV
types examined.
We found a signiﬁcant association between hair color and gamma
HPV positivity (p=0.009), with blonde and red-haired people having
lower prevalence than those with dark hair. Fair-skinned people had
higher gamma, skin and mucosal alpha HPV seropositivity than those
with darker skin (all three p values b0.05). Signiﬁcantly higher
seropositivity to the mu and nu HPV types were found for people that
reported burning only as a response to strong sun exposure compared
with people that tanned only (pb0.0001). Conversely, seroprevalence
to the mucosal alpha types was higher in those who tanned compared
with those who burnt easily (p=0.013). Smokers had a signiﬁcantly
higher seroprevalence for beta and both skin and mucosal alpha HPV
types than non-smokers (p=0.001, 0.012 and 0.012, respectively;
Table 2).
HPV-75 antibodies were less prevalent in people that had been
diagnosed with BCC (p=0.039) but there was no association between
BCC and antibodies to any other type or speciﬁc genus. Actinic
keratosis was associated with seropositivity to at least one beta or
gamma HPV type (p=0.040 and p=0.012, respectively).
Fig. 1. Seroprevalence for men and women for all 37 HPV antibodies analyzed at baseline (1992). Blue bar — male seroprevalence, Red bar — female seroprevalence.
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We analyzed changes in HPV antibodies over time by examining
changes in serostatus (positive versus negative) and also in MFI with
no cut-off speciﬁed. In each case we stratiﬁed the analysis according
to baseline serostatus.
Over 90% of people that were seronegative at baseline stayed
seronegative during the 4½ year follow-up and people that changed
status were more likely to seroconvert than to ﬂuctuate (Supplemen-
tary Table 2). The highest serostability in people seronegative at
baseline was seen for HPV-88 (99.7% remained seropositive or
seronegative), while HPV-65 was least stable with 15% of those
negative at baseline altering their serostatus (seroconversion or
ﬂuctuation) during follow-up. Seroprevalence to the beta HPV types
increased signiﬁcantly from year 1992 to 1996 (ptrend=0.031;
Table 2).
In participants seropositive at baseline there was greater variabil-
ity in serostability across types. For example, of the 36 people positive
for HPV-5, 20 either seroreverted or had ﬂuctuating status over the
4.5 years, while for HPV-3 32 of the 36 people who were positive at
baseline remained positive. Across all HPV types, on average 80% of
people seropositive at baseline remained seropositive (Supplemen-
tary Table 2).
We investigated the extent to which ﬂuctuation was due to MFI
values being close to the cut-off in the HPV types where there were at
least 15% of people ﬂuctuating. For HPV-5 and HPV-23, 15 people had
ﬂuctuating serostatus, and for each type 67% (10/15) had at least one
of the three MFI values within 50 MFI units of the cut-off. Twelve out
of the 15 people (80%) with ﬂuctuating HPV-22 serostatus, 11 out of
the 17 for HPV-80 (65%) and 15 out of 16 for HPV-63 (94%) also had at
least one of the MFI values within 50 MFI units of the cut-off.
With a few exceptions, there was little difference in serostability
betweenmen andwomen. For HPV-49, womenweremore likely to be
stably seropositive or seronegative than men (p=0.008). In women,
93% (N=41) of those HPV-49 seropositive at baseline remained
seropositive compared with 75% (N=42) of men, and 97% of
seronegative women remained seronegative compared with 88% of
men (p=0.005). Women's serum antibody status was also signiﬁ-
cantly more stable than men's for HPV-23, HPV-65 and HPV-95, with
men more likely to serorevert for HPV-23 and more likely toseroconvert for the latter two. No associations between serostability
and any other characteristics (age, skin type, diagnosis of BCC or AK)
were found. People diagnosed with BCC or AK at baseline or with BCC
between 1992 and 1996 were not more likely to seroconvert than
people who were not newly diagnosed with skin lesions.
We used linear regression to investigate changes in MFI over the
three time points for selected HPV types stratiﬁed by serostatus at
baseline and adjusted for sex and age (Table 3). People who were
seronegative for HPV-8, HPV-38, HPV-4, HPV-1 and HPV-16 at
baseline had signiﬁcantly increasing MFI over time (pb0.05 for all
ﬁve HPV types; Table 3). The group of people that was HPV-38
seropositive at baseline also had signiﬁcantly increasingMFI over time
(p=0.025), but there were no signiﬁcant trends for the people that
were seropositive to the other HPV types investigated. In most cases
there was a decrease in MFI in 1993 but a return to baseline levels in
1996. Despite changes in MFI, changing the cut-off used to determine
positivity did not substantially alter the proportion of people who
remained serostable for most types.
Discussion
Previous studies of HPV antibodies have mostly focused on the
high-risk HPV types from the alpha genus, and cutaneous HPVs have
been studied less extensively. To our knowledge, this is the ﬁrst
longitudinal serology study investigating the stability of antibodies to
different cutaneous HPV types. We investigated seroprevalence and
antibody stability over 4½ years for 37 different HPV types in 390
people. At baseline, 86% of participants were seropositive to at least
one of the HPV types analyzed, which is similar to recent reports from
the United Kingdom and Florida (86–91%) (Casabonne et al., 2009;
Iannacone et al., 2010), but higher than has been reported in European
studies (20–60%) (Casabonne et al., 2007; Michael et al., 2008).
However, comparisons of overall seropositivity are arguably inappro-
priate due to variability in the types and number of different
HPVs tested, along with variation resulting from different testing
techniques.
We found HPV-4 to have the highest seroprevalence (41%). High
HPV-4 seroprevalence has been reported in previous studies from
Queensland (35%) (Waterboer et al., 2009), Florida (46%) (Iannacone
et al., 2010) and the United Kingdom (31%) (Casabonne et al., 2007).
Table 2
Associations with HPV seropositivity, grouped by phylogenetic genera and adjusted for age and sex. Signiﬁcant P values in bold.
Characteristic Any
β-HPV
positive
(%)a
OR (95% CI) P value (Ptrend) Any
γ-HPV
positive
(%)b
OR (95% CI) P value (Ptrend) Any
μ/ν HPV
positive
(%)c
OR (95% CI) P value
(Ptrend)
Skin
α-HPV
positive
(%)d
OR (95% CI) P value
(Ptrend)
Mucosal
α-HPV
positive
(%)e
OR (95% CI) P value
(Ptrend)
Total % (n) 64.9 – – 59.9 – – 35.9 – – 14.8 – – 25.7 – -
Age distribution:
up to 40 62.5 1.00 0.601
(0.022)
56.0 1.00 0.151
(0.939)
43.3 1.00 0.511
(0.018)
16.7 1.00 0.107
(0.017)
33.3 1.00 0.143
(0.0002)40–50 61.5 0.96 (0.57–1.62) 59.4 1.14 (0.69–1.90) 32.8 0.66 (0.39–1.10) 18.5 1.16 (0.59–2.30) 25.4 0.67 (0.39–1.13)
50–60 66.8 1.17 (0.66–2.08) 68.2 1.61 (0.94–2.76) 36.1 0.72 (0.40–1.30) 9.3 0.50 (0.21–1.19) 25.2 0.68 (0.38–1.22)
60–70 67.2 1.22 (0.66–2.25) 62.4 1.28 (0.71–2.32) 32.3 0.64 (0.34–1.19) 16.1 0.95 (0.43–2.10) 20.4 0.51 (0.27–0.99)
70 and older 75.3 1.78 (0.74–4.25) 45.2 0.63 (0.29–1.34) 32.3 0.62 (0.28–1.41) 7.5 0.40 (0.10–1.55) 16.1 0.38 (0.15–0.96)
Sex: Female 58.3 1.00 0.0008 55.1 1.00 0.019 28.2 1.00 0.0001 12.5 1.00 0.083 28.8 1.00 0.085
Male 73.4 1.97 (1.32–2.90) 66.0 1.56 (1.08–2.27) 45.8 2.19 (1.47–3.25) 17.7 1.60 (0.94–2.71) 21.8 0.69 (0.46–1.05)
Eye color: Dark brown 71.9 1.00 0.056 57.0 1.00 0.285 34.1 1.00 0.285 21.7 1.00 0.201 26.8 1.00 0.102
Light brown 63.2 0.60 (0.24–1.53) 64.0 1.36 (0.58–3.28) 33.3 0.98 (0.65–2.25) 14.9 0.67 (0.31–1.48) 33.3 1.49 (0.62–3.55)
Hazel/green 64.0 0.62 (0.32–1.21) 65.3 1.38 (0.75–2.47) 34.0 1.00 (0.53–1.48) 11.2 0.45 (0.20–1.04) 28.7 1.16 (0.58–2.35)
Blue/grey 63.9 0.58 (0.30–1.15) 55.2 0.94 (0.52–1.66) 38.9 1.21 (0.65–2.25) 16.2 0.67 (0.31–1.48) 21.3 0.81 (0.40–1.63)
Hair color:
Dark brown/
Black
68.4 1.00 0.113 64.0 1.00 0.009 33.7 1.00 0.065 17.3 1.00 0.115 27.7 1.00 0.706
Blonde/Light
brown
62.7 0.80 (0.53–1.21) 58.6 0.83 (0.56–1.23) 38.0 1.36 (0. 90–2.06) 13.1 0.77 (0.44–1.33) 22.4 0.74 (0.48–1.14)
Red 60.2 0.79 (0.40–1.60) 46.2 0.53 (0.25–1.11) 34.4 1.22 (0.56–2.63) 11.8 0.70 (0.23–2.09) 35.5 1.31 (0.66–2.57)
Skin color: Dark 73.0 1.00 0.103 51.3 1.00 0.044 25.2 1.00 0.739 12.6 1.00 0.022 37.8 1.00 0.012
Medium 66.1 0.77 (0.36–1.66) 59.6 1.43 (0.75–2.72) 41.4 2.19 (1.02–4.71) 12.1 0.97 (0.34–2.76) 24.2 0.49 (0.24–1.00)
Fair 62.6 0.68 (0.32–1.43) 61.6 1.61 (0.85–3.03) 33.8 1.65 (0.76–3.48) 17.2 1.50 (0.56–4.07) 24.7 0.48 (0.24–0.94)
Skin response to strong
sun exposure:
Tan only 54.5 1.00 0.070 60.2 1.00 0.325 24.4 1.00 b0.0001 10.6 1.00 0.676 30.1 1.00 0.013
Burn, then tan 67.3 2.13 (1.11–4.12) 58.8 0.90 (0.48–1.70) 35.5 1.75 (0.80–3.84) 16.4 1.52 (0.54–4.27) 25.9 0.65 (0.32–1.29)
Burn only 62.0 1.92 (0.91–4.06) 63.6 1.14 (0.54–2.43) 43.6 2.88 (1.17–7.02) 11.1 1.04 (0.32–3.40) 22.7 0.50 (0.23–1.11)
Type of occupation:
Mainly indoors 62.5 1.00 0.518 60.6 1.00 0.123 35.0 1.00 0.685 13.7 1.00 0.574 28.1 1.00 0.996
Out–and indoors 65.7 1.09 (0.70–1.71) 57.6 0.78 (0. 51–1.20) 32.6 0.99 (0.55–1.80) 14.3 1.07 (0.58–1.97) 24.0 0.99 (0.61–1.60)
Mainly outdoors 69.9 1.10 (0.59–2.06) 62.9 1.10 (0.70–1.62) 45.5 1.24 (0.78–1.98) 18.7 1.19 (0.57–2.50) 23.2 0.98 (0.52–1.91)
Smoking: Never 58.9 1.00 0.001 59.0 1.00 0.270 30.4 1.00 0.141 11.5 1.00 0.012 23.7 1.00 0.012
Current 74.5 1.91 (0.88–4.16) 69.6 1.40 (0.71–2.75) 49.0 1.88 (0.92–3.85) 20.6 1.89 (0.76–4.65) 31.4 1.57 (0.72–3.40)
Ex-smoker 72.0 1.56 (1.00–2.42) 58.9 0.84 (0.55–1.27) 41.2 1.37 (0.88–2.14) 18.5 1.60 (0.88–2.93) 27.6 1.45 (0.92–2.28)
Basal cell carcinoma: No 64.7 1.00 0.828 59.2 1.00 0.777 35.7 1.00 0.798 14.8 1.00 0.868 25.6 1.00 0.616
Yes 65.7 1.06 (0.64–1.73) 62.8 1.08 (0.67–1.75) 36.7 1.07 (0.63–1.82) 15.0 1.06 (0.54–2.08) 26.6 1.15 (0.67–2.00)
Actinic keratosis No 63.8 1.00 0.291 58.3 1.00 0.092 35.7 1.00 0.862 14.9 1.00 0.803 26.2 1.00 0.798
Yes 72.1 1.37 (0.75–2.53) 69.8 1.62 (0.90–2.88) 37.1 1.05 (0.59–1.89) 13.8 0.90 (0.40–2.03) 22.6 0.91 (0.48–1.76)
Year 1992 62.5 1.00 60.3 1.00 34.6 1.00 14.1 1.00 24.4 1.00
1993 63.1 1.01 (0.88–1.17) 0.0002 56.9 0.87 (0.75–1.00) 0.004 35.4 1.04 (0.90–1.19) 0.065 15.1 1.09 (0.91–1.31) 0.597 24.6 1.01 (0.86–1.20) 0.072
1996 69.1 1.35 (1.15–1.57) (0.031) 62.5 1.10 (0.93–1.31) (0.304) 37.7 1.15 (1.02–1.30) (0.341) 15.1 1.09 (0.91–1.31) (0.744) 28.2 1.22 (1.02–1.47) (0.173)
a β-HPV types analyzed: HPV-5, -8, -9, -14, -15, -17, -20, -21, -22, -23, -24, -36, -38, -47, -49, -75, -76, -80, -92, -93, -96 and -107.
b γ-HPV types: HPV-4, -48, -50, -65, -88, -95, -101 and -103.
c μ/ν HPV types: HPV-1, -63 and -41.
d Skin α-HPV types: HPV-2 and -3.
e Mucosal α-HPV types: HPV-11 and -16.
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Table 3
Association between MFI values and the year of serum collection, expressed as the ratio of the geometric means with 1992 used as the reference category. Results are stratiﬁed by
serostatus at baseline and adjusted for sex and age. Signiﬁcant P values are in bold.
1992 1993 1996
Mean Median Ratioa (REF) Mean Median Ratioa (95% CI) Mean Median Ratioa (95% CI) Ptrend
HPV-8
Seropositive 1577 811 1.00 1446 810 0.93 (0.84–1.02) 1580 687 1.06 (0.96–1.17) 0.100
Seronegative 48 32 1.00 43 26 0.89 (0.78–1.02) 50 33 1.16 (1.01–1.33) 0.006
HPV-38
Seropositive 1785 669 1.00 1556 718 0.98 (0.88–1.09) 1709 709 1.09 (0.99–1.19) 0.025
Seronegative 49 32 1.00 48 29 0.84 (0.74–0.95) 46 33 1.01 (0.88–1.15) 0.004
HPV-4
Seropositive 1099 730 1.00 1048 940 0.91 (0.85–0.97) 1067 720 0.96 (0.90–1.03) 0.674
Seronegative 44 22 1.00 47 29 0.96 (0.86–1.08) 48 27 1.15 (1.02–1.29) 0.006
HPV-1
Seropositive 956 558 1.00 877 590 0.91 (0.84–0.98) 861 511 0.93 (0.84–1.04) 0.381
Seronegative 30 9 1.00 28 8 0.97 (0.89–1.05) 29 10 1.08 (0.99–1.18) 0.036
HPV-16
Seropositive 918 418 1.00 917 508 1.02 (0.86–1.21) 1067 477 1.17 (0.97–1. 04) 0.085
Seronegative 46 30 1.00 48 33 0.94 (0.86–1.03) 52 39 1.26 (1.17–1.36) b0.0001
a Ratio of the geometric mean generated from the linear regression model, using the log of the MFI value as the outcome variable.
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common cutaneous warts which are highly prevalent in the general
population, especially in children and adolescents (Chen et al., 1993;
Kilkenny et al., 1998). The second most seroprevalent type and the
most common beta type in our study population was HPV-8. This is
consistent with other reports (Andersson et al., 2008; Karagas et al.,
2006; Michael et al., 2008), and the seroprevalence is almost identical
to that reported for a different Queensland population (Waterboer
et al., 2009). Furthermore, other type-speciﬁc seroprevalences shown
here are similar to those previously reported in Caucasians and show
that seroprevalence to skin HPV types have a similar worldwide
distribution.
As in previous studies (Feltkamp et al., 2003; Karagas et al., 2006;
Waterboer et al., 2008, 2009), we found that men generally have
higher HPV seroprevalence than women, particularly for beta,
gamma, mu and nu HPV types. The reason for this difference is
unclear, but similar ﬁndings for HPV DNA in plucked eye brow hairs
have also been reported (Struijk et al., 2003) suggesting that the
difference may be related to propensity for infection rather than to
whether or not antibodies are produced.
Seroprevalence to HPV-1, one of the HPV types causing common
warts, was signiﬁcantly higher in people younger than 50 years than
in older people. Comparable ﬁndings have been reported in a
population-based German study (Michael et al., 2008). The low-risk
alpha HPV type, HPV-11, was also more commonly found in younger
participants. It has been shown that antibodies to high-risk mucosal
HPV types are more stable over time than antibodies to low-risk types
which seem to decay 1 to 2 years after the infection has been cleared
(Carter et al., 2000). Genital HPV infections are more prevalent in
younger people and loss of seropositivity over time could explain why
seroprevalence to HPV-11 decreases with higher age.
We found that fair-skinned people had higher seroprevalence for
gamma and skin alpha HPV types than those with darker skin. This is
consistent with a recent study from Florida (Iannacone et al., 2010).
The reason for this is unknown, but it is possible that fair-skinned
people have had a greater number of sunburns which may increase
the likelihood of seroconversion (Favre et al., 2000).
Current smokers had signiﬁcantly higher seroprevalence to HPV
types from the alpha genus compared to non-smokers. However
without information about potential confounders, such as the number
of sexual partners, we cannot assess whether or not this association is
causal. Smokers also had signiﬁcantly higher prevalence of beta HPV
types. Some previous studies have found smoking to be associated
with beta HPV seropositivity (Andersson et al., 2008; Iannacone et al.,
2010), while others have not found any association (Casabonne et al.,2009) but this inconsistency may be due to analysis of different
numbers and types of beta HPV.
We did not ﬁnd any associations between the presence of
antibodies from any HPV genera and a diagnosis of actinic keratosis
at baseline. Two previous studies have found higher HPV-8 seropos-
itivity in patients with actinic keratosis (Bouwes Bavinck et al., 2000;
Struijk et al., 2006) while another did not ﬁnd any association
(Andersson et al., 2008). Actinic keratosis is one of the known
precursors to cutaneous SCC, and it has been estimated that
approximately 10% of actinic keratoses progress to SCC (Boukamp,
2005). HPV seroprevalence in relation to cutaneous SCCs has been
studied in more detail and while most studies ﬁnd higher seropre-
valence in SCC patients than in controls, others have not identiﬁed any
associations between HPV seropositivity and SCC (Andersson et al.,
2008; Casabonne et al., 2009, 2007; Feltkamp et al., 2003; Karagas et
al., 2006). Additional work is needed to clarify the role of HPV in the
etiology of actinic keratosis and cutaneous SCCs.
There is limited information about HPV antibody stability over
time, and the studies available have studied the most common alpha
HPV types in womenwhich havemucosal tropism (Carter et al., 2000;
Syrjanen et al., 2009; Wang et al., 2004). We found cutaneous HPV
antibodies to be relatively stable over 4½ years. The HPV types where
we observed larger changes were those with low seroprevalence,
leading to statistical instability. For most HPV types the majority of
people retained their seropositive or seronegative status over time.
The most common change was seroreversion (loss of seropositivity)
while seroconversion and ﬂuctuation of antibody levels occurred less
frequently. Antibody levels for the mucosal high-risk HPV types that
are the causative agents of cervical cancer are usually stable over time
with little or no variation (af Geijersstam et al., 1998; Carter et al.,
1996; Shah et al., 1997). In contrast, antibodies to low-risk HPV types
seems to decay within two years after the infection has been cleared
(Carter et al., 2000). In this study we did observe a slightly higher
proportion of people seroreverting for HPV-11 (low-risk) than for
HPV-16 (high risk). However, our population was considerably older
than those studied previously and consisted of both women and men.
We recognize that the cut-off value used in this study is arbitrary.
However this is a common feature of most cutaneous HPV serology
studies, as long as there are no reference sera to use as standards. We
observed variations in MFI values over time, even in those whose
antibody status based on a categorization of theMFI did not change. In
general, the MFI was higher in 1996 than in 1992, although in most
cases there was a small decrease in MFI in 1993. This may be due to
physiological variation, but sample storage, other methodological
issues or longer follow-up time could be responsible for the variability
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serostability were relatively robust to changes in MFI values.
It has been suggested that diagnosis of skin lesions might lead to
inﬂammatory changes that either increase HPV proliferation or lead to
presentation of HPV to the immune system leading to an antibody
response (Favre et al., 2000). However we found no evidence that a
diagnosis of AK or BCC increased the rate of seroconversion.
We conductedmany different analyses, and it is likely that some of
the associations we found with HPV seropositivity arose due to
chance. Our participants were all over 26 years limiting the
generalisability of these ﬁndings to younger people, and we do not
know if the stability we observed here would persist over a longer
follow-up time. However, the participants in the Nambour Skin Study
have been shown to be similar to the population from which they
were drawn (Green et al., 1999), andwe did not ﬁnd any demographic
or behavioral differences between the 390 people included in this
study and the remainder of the original cohort (n=1231) who did
not have three serum samples collected and analyzed.
To conclude, we found that the majority of the Australian adults
investigated here were seropositive to at least one cutaneous HPV
type. Furthermore, seroprevalence to the cutaneous HPV types
appears to be largely very stable over the time period investigated.
This would suggest that measuring antibodies at a single time point is
appropriate in studies aiming to understand disease associations.
Materials and methods
Study population
This study was a part of the Nambour Skin Cancer Study which has
previously been described in detail (Green et al., 1999). Brieﬂy, in
1992 1621 randomly selected members of the Nambour Township in
southeast Queensland, Australia were enrolled in a trial of sunscreen
and beta-carotene for the prevention of skin cancer. All participants
completed questionnaires in which information about skin phenotype
and sun exposure was obtained. Serum samples were collected from
693 randomly selected participants in 1992, 549 in 1993, and 1211 in
1996. In this study, we analyzed data and sera for 390 people who had
blood collected in 1992, 1993 and 1996 and who had never been
diagnosed with cutaneous SCC. The subgroup of 390 people had
similar characteristics to the remainder of the Nambour cohort (mean
age 50 years (range 26 to 76 years) and 55% female).
This study was approved by the Ethics Committee at the Queens-
land Institute for Medical Research and all participants gave written
informed consent.
HPV serology analysis
Serum samples were stored at −80 °C and shipped on dry ice to
the German Cancer Research Center (DFKZ), Heidelberg, Germany.
The samples were analyzed for antibodies to the capsid protein (L1) of
the following 37 HPV types; beta types HPV-5, -8, -9, -14, -15, -17, -20,
-21, -22, -23, -24, -36, -38, -47, -49, -75, -76, -80, -92, -93, -96 and
-107; gamma types HPV-4, -48, -50, -65, -88, -95, -101 and -103; mu
types HPV-1 and -63, the nu type HPV-41, the cutaneous alpha types
HPV-2 and -3, and the mucosal alpha types HPV-11 and -16 (Bernard
et al., 2010). The antibody detectionmethodwas based on glutathione
S-transferase (GST) capture ELISA (Sehr et al., 2001) in combination
with ﬂuorescent bead technology (Waterboer et al., 2005). Brieﬂy,
full-length viral proteins were expressed in bacteria in fusion with an
N-terminal GST-domain. Glutathione cross-linked to casein was
coupled to ﬂuorescence-labeled polystyrene beads (SeroMap, Lumi-
nex, Austin, TX) and GST-fusion proteins were afﬁnity-puriﬁed on the
beads. Bead types of different color and each carrying a different
antigen weremixed and incubated with human sera at 1:100 dilution.
Antibody bound to the beads via the viral antigens was stainedby biotinylated anti-human-Ig and streptavidin-R-phycoerythrin.
A Luminex analyser (xMAP, Luminex) was used to identify the
internal color of the individual beads and to quantify their reporter
ﬂuorescence (expressed as median ﬂuorescence intensity (MFI) of at
least 100 beads per set per serum).
Statistical analysis
All analysis was carried out using SAS 9.1. Cut-points to determine
antibody positivity were selected by visual inspection of the
distribution of MFI values among all study participants (Carter et al.,
2009), and seropositivity was deﬁned as having anMFI value of 200 or
more (Michael et al., 2008). Factors associated with positivity were
analyzed using logistic regression with generalized estimating
equations (GEE) to take account of serostatus at all three time points.
In order to analyze HPV antibody stability over time we classiﬁed
participants as being seropositive at all time points (stably seropos-
itive), seronegative at all time points (stably seronegative), serocon-
verting (change from seronegative to seropositive over time),
seroreverting (change from seropositive to seronegative) and ﬂuctu-
ating between seropositive and seronegative over the three time
points (ﬂuctuating). Chi-squared tests were used to analyze associa-
tions between variables such as age, sex, skin type, sun exposure, BCC,
actinic keratosis (AK) and antibody prevalence and stability.
In addition, for ﬁve HPV types selected to represent the most
common type in each genus, we examined changes in MFI over time
using linear regression with GEE to account for intra-person
correlation. Because MFI was not normally distributed, we used the
log of the MFI value as the outcome variable in each analysis, and
expressed the results as the ratio in the geometric means using 1992
as the reference point. These analyses were stratiﬁed by serostatus at
baseline and adjusted for age and sex.
Supplementary data to this article can be found online at
doi:10.1016/j.virol.2010.07.046.
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